Investor Library
| April 11, 2023 | Timely Disclosure Information | [Delayed] StemRIM Announces Preliminary Results from Phase 2 Clinical Trial of Redasemtide in Patients with Chronic Liver Disease |
|---|---|---|
| April 11, 2023 | Timely Disclosure Information | [Delayed] Notice of Earnings Forecasts for the Fiscal Year Ending July 31, 2023 |
| April 11, 2023 | Timely Disclosure Information | [Delayed] StemRIM Announces Milestone Achievement in Development of Therapeutic Drug (Redasemtide) Targeting Acute Ischemic Stroke |